These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34383102)

  • 41. A Pragmatic Scoring Tool to Predict Hydroxyurea Response Among β-Thalassemia Major Patients in Pakistan.
    Ansari SH; Hussain Z; Zohaib M; Parveen S; Kaleem B; Qamar H; Adil O; Khan MT; Shamsi TS
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e77-e83. PubMed ID: 33710118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea.
    Olivieri NF; Rees DC; Ginder GD; Thein SL; Brittenham GM; Waye JS; Weatherall DJ
    Lancet; 1997 Aug; 350(9076):491-2. PubMed ID: 9274590
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study.
    Italia KY; Jijina FF; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    J Clin Pathol; 2010 Feb; 63(2):147-50. PubMed ID: 20154037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from Eastern India.
    Bohara VV; Ray S; Chakrabarti P; Ray SS; Nath UK; Chaudhuri U
    Hemoglobin; 2014; 38(1):44-8. PubMed ID: 24144212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
    Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
    Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
    Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
    Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacoproteomics Profiling of Plasma From β-Thalassemia Patients in Response to Hydroxyurea Treatment.
    Zohaib M; Ansari SH; Shamsi TS; Zubarev RA; Zarina S
    J Clin Pharmacol; 2019 Jan; 59(1):98-106. PubMed ID: 30152032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do alpha deletions influence hydroxyurea response in thalassemia intermedia?
    Panigrahi I; Dixit A; Arora S; Kabra M; Mahapatra M; Choudhry VP; Saxena R
    Hematology; 2005 Feb; 10(1):61-3. PubMed ID: 16019448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM; Taher AT; Cappellini MD; Sankaran VG
    Blood; 2013 Mar; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The bone density of thalassemic patients of Boo Ali Sina Hospital, Sari, Iran in 2002 does hydroxyurea help?
    Kosaryan M; Zadeh MF; Shahi VK
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():303-6. PubMed ID: 16462716
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
    Karimi M; Zarei T; Haghpanah S; Moghadam M; Ebrahimi A; Rezaei N; Heidari G; Vazin A; Khavari M; Miri HR
    J Pediatr Hematol Oncol; 2017 May; 39(4):e171-e176. PubMed ID: 28121747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    de Montalembert M; Voskaridou E; Oevermann L; Cannas G; Habibi A; Loko G; Joseph L; Colombatti R; Bartolucci P; Brousse V; Galactéros F;
    Am J Hematol; 2021 Oct; 96(10):1223-1231. PubMed ID: 34224583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
    Huang SZ; Ren ZR; Chen MJ; Xu HP; Zeng YT; Rodgers GP; Zeng FY; Schechter AN
    Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
    Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia.
    Rigano P; Rodgers GP; Renda D; Renda MC; Aquino A; Maggio A
    Hemoglobin; 2001 Feb; 25(1):9-17. PubMed ID: 11300353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.